House Dust Mite Allergy Market Size - Analysis
Market Size in USD Bn
CAGR13.6%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 13.6% |
| Market Concentration | Medium |
| Major Players | ALK-Abelló A/S, Stallergenes Greer, HAL Allergy Group, Allergy Therapeutics, Anergis SA and Among Others |
please let us know !
House Dust Mite Allergy Market Trends
House dust mite allergies have been on the rise across the globe in recent decades. Rising temperatures and humidity levels allow dust mites to multiply rapidly throughout the year instead of just during certain seasons. This has led to perennial exposure and increased sensitivity among people.
Stressful urban lifestyles too have weakened immunity for some individuals. Furthermore, greater awareness among public and medical professionals has led to higher diagnosis rates in recent times. People are more conscious about symptoms and able to detect dust mite allergies early on.
Pharmaceutical firms are continuously striving to develop novel immunotherapy solutions that offer convenience to patients. One such innovation is sublingual immunotherapy or SLIT. SLIT has gained popularity due to its comfort and ease of use at home settings. Patients can self-administer the allergen tablets or drops daily without any medical supervision. This enables continuous therapy and makes it more acceptable for long-term compliance.
Biotech firms continue enhancing SLIT further through novel drug delivery systems. Fast-dissolving strips and orally disintegrating tablets are now available that take seconds to administer. Such innovations will further strengthen patient acceptance of SLIT. As immunotherapies like SLIT gain ground, they will expand the treatable population and drive continued market evolution in coming years.
One of the key challenges currently faced in the house dust mite allergy market is the expensive immunotherapy treatments available. Immunotherapy, also known as allergy shots or desensitization, is currently the only treatment that can cure house dust mite allergies by modifying the immune system's response.
The long duration of treatment also poses compliance challenges as patients have to diligently follow the treatment schedule for years. drug manufacturers need to focus on developing more affordable immunotherapy treatments or alternatives that can help address this market challenge.
Market Opportunity - Expanding Healthcare Infrastructure in Asia-Pacific
At the same time, growing pollution and dust mite infestation levels attributed to urbanization are contributing to a rise in allergic conditions like house dust mite allergy. This is increasing the patient population that needs treatment. The enhanced healthcare infrastructure in Asia-Pacific makes it easier for patients to obtain diagnosis and treatment. It also allows global manufacturers to enter these emerging markets.
Prescribers preferences of House Dust Mite Allergy Market
House dust mite allergy is typically treated via a step-wise approach depending on the severity of symptoms. For mild intermittent symptoms, over-the-counter antihistamines such as loratadine (Claritin) and cetirizine (Zyrtec) are often recommended on an as-needed basis.
Patients with moderate-severe persistent symptoms typically require combination therapy. Prescribers commonly add leukotriene receptor antagonists such as montelukast (Singulair) to an intranasal corticosteroid. For more severe, uncontrolled cases, prescribers may consider subcutaneous or sublingual immunotherapy as a long-term maintenance treatment. The builds gradual tolerance to dust mite allergens. Brands include Oralair and Grazax.
Treatment Option Analysis of House Dust Mite Allergy Market
House dust mite allergy can be classified into mild, moderate, and severe based on symptoms. For mild intermittent symptoms, over-the-counter (OTC) antihistamines like cetirizine or loratadine are preferred.
For inadequately controlled or severe persistent symptoms, a combination of an antihistamine with a nasal corticosteroid spray is prescribed. Common prescription combinations include Reactine with Flonase, Clarinex D 12 HR, and Aerius C. Fluticasone propionate (Flonase) is the most preferred nasal corticosteroid due to its high safety profile.
Severe persistent asthma induced by dust mite allergy may require controller inhalers like low dose ICS (fluticasone), ICS-LABA (Symbicort) or long-acting bronchodilators like montelukast (Singulair). Controller therapy aims to reduce exacerbations along with other treatment options.
Key winning strategies adopted by key players of House Dust Mite Allergy Market
Product innovation - Introducing novel products to directly target the root cause of dust mite allergies has been an effective strategy. For example, in 2015, ALK released Grazax, an oral immunotherapy tablet made from house dust mite allergens.
Awareness campaigns - Increasing education about dust mite allergies and available solutions has driven demand. For example, between 2010-2015, Stallergenes Greer ran the "yourAllergy" global program, educating 200K people via websites and social media. This likely contributed to sales of their sublingual immunotherapy tablets like Oralair rising by 29% in 2015.
Segmental Analysis of House Dust Mite Allergy Market
Insights, By Treatment: Effective Remedies Drive Pharmacotherapy's High Usage
Antihistamines are widely used due to their dual ability to reduce sneezing, itching, and runny nose by blocking allergic histamine release. Nasal corticosteroids are also popular for their potent anti-inflammatory action, making them highly effective at reducing nasal congestion.
In terms of diagnosis, skin prick tests are projected to hold 50.8% share of the house dust mite allergy market in 2024, owing to their convenience and accuracy. Skin prick tests are valued as they can identify allergens in 10-15 minutes with just a small amount of allergen extract and the patient's skin. This immediacy helps physicians rapidly determine allergens responsible for symptoms and customize treatment accordingly.
In terms of allergy type, respiratory allergies contribute the highest share of the house dust mite allergy market owing to the vast prevalence of allergic rhinitis. Allergic rhinitis, commonly known as hay fever, affects over 500 million people globally annually, accounting for more than half of respiratory allergy cases. Sneezing, congestion, and runny nose caused by allergic rhinitis can greatly diminish quality of life.
Additional Insights of House Dust Mite Allergy Market
- Global Prevalence: House dust mite allergy affects approximately 10-20% of the global population, making it one of the most common allergic conditions worldwide.
- Market Trends: There is a noticeable shift towards sublingual immunotherapy (SLIT) due to its convenience over traditional subcutaneous methods, leading to higher patient compliance and better outcomes.
- House dust mite allergy is one of the most common indoor aeroallergens, affecting a large percentage of individuals with allergic rhinitis and asthma.
- Immunotherapy remains a long-term treatment option for severe allergy sufferers but has seen slower uptake due to cost and patient compliance issues.
- Increased Research Activities: There is a growing focus on developing hypoallergenic vaccines and novel immunotherapies for house dust mite allergies, which could revolutionize treatment approaches.
Competitive overview of House Dust Mite Allergy Market
The major players operating in the house dust mite allergy market include ALK-Abelló A/S, Stallergenes Greer, HAL Allergy Group, Allergy Therapeutics, Anergis SA, T-Balance Therapeutics, Worg Pharmaceuticals, Advagene Biopharma Co., Ltd., Immunotek SL, Tolerogenics S.à.r.l., and Foresee Pharmaceuticals.
House Dust Mite Allergy Market Leaders
- ALK-Abelló A/S
- Stallergenes Greer
- HAL Allergy Group
- Allergy Therapeutics
- Anergis SA
House Dust Mite Allergy Market - Competitive Rivalry
House Dust Mite Allergy Market
(Dominated by major players)
(Highly competitive with lots of players.)
Recent Developments in House Dust Mite Allergy Market
- In October 2023, T-Balance Therapeutics announced a new phase of clinical trials for its immunomodulatory therapy aimed at reducing allergy severity. The study promises to enhance treatment effectiveness and lower adverse reactions. The company has been actively working on tregalizumab, a monoclonal antibody designed to activate regulatory T cells (Tregs). This therapy has shown promise in treating various immune-mediated conditions, including allergic asthma.
- In June 2023, Worg Pharmaceuticals introduced an innovative allergen formulation targeting long-term desensitization, which shows potential in reducing allergic reactions to dust mites. Worg Pharmaceuticals is actively involved in the development of treatments for allergies, including those for house dust mites. Their work includes advanced immunotherapies aimed at addressing allergic diseases using platforms like PCFiT, which focuses on creating more effective allergen immunotherapies.
- In June 2021, ALK-Abelló A/S received FDA approval for its house dust mite sublingual immunotherapy tablet, ODACTRA, for use in the United States. ODACTRA is designed for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, for patients aged 12 to 65 years. This approval expanded the treatment options for patients suffering from house dust mite allergies, allowing them to undergo sublingual immunotherapy (SLIT) rather than relying solely on traditional methods like injections.
- In April 2021, Stallergenes Greer announced positive results from a Phase III clinical trial evaluating its new sublingual immunotherapy tablet, STAGR320, for treating house dust mite (HDM)-induced allergic rhinitis. The trial met its primary efficacy endpoint, demonstrating significant symptom improvement in patients compared to a placebo. Over 1,600 patients across multiple countries participated in this large-scale, double-blind, placebo-controlled study. The successful outcomes set the stage for Stallergenes Greer to pursue further market registrations for the treatment in Europe and other regions.
House Dust Mite Allergy Market Segmentation
- By Treatment
- Pharmacotherapy
- Antihistamines
- Decongestants
- Nasal Corticosteroids
- Leukotriene Receptor Antagonists
- Immunotherapy
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
- Oral Immunotherapy
- Pharmacotherapy
- By Diagnosis
- Skin Prick Tests
- Specific IgE Blood Tests
- Patch Tests
- By Allergy Type
- Respiratory Allergies
- Allergic Rhinitis
- Allergic Asthma
- Dermatological Allergies
- Atopic Dermatitis
- Eczema
- Respiratory Allergies
Would you like to explore the option of buyingindividual sections of this report?
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Frequently Asked Questions :
How big is the house dust mite allergy market?
The house dust mite allergy market is estimated to be valued at USD 2.6 Bn in 2024 and is expected to reach USD 5.3 Bn by 2031.
What are the key factors hampering the growth of the house dust mite allergy market?
The expensive immunotherapy treatments and inadequate knowledge about allergy management in developing regions are the major factor hampering the growth of the house dust mite allergy market.
What are the major factors driving the house dust mite allergy market growth?
The increasing global incidence of house dust mite allergies and development of patient-friendly immunotherapies like slit are the major factor driving the house dust mite allergy market.
Which is the leading treatment in the house dust mite allergy market?
The leading treatment segment is pharmacotherapy.
Which are the major players operating in the house dust mite allergy market?
ALK-Abelló A/S, Stallergenes Greer, HAL Allergy Group, Allergy Therapeutics, Anergis SA, T-Balance Therapeutics, Worg Pharmaceuticals, Advagene Biopharma Co., Ltd., Immunotek SL, Tolerogenics S.à.r.l., and Foresee Pharmaceuticals are the major players.
What will be the CAGR of the house dust mite allergy market?
The CAGR of the house dust mite allergy market is projected to be 13.6% from 2024-2031.